The kin-cohort study for estimating penetrance

American Journal of Epidemiology

Volumn 148, Issue 7, 1998, Pages 623-630

  Wacholder, Sholom ^a   Hartge, Patricia ^a   Struewing, Jeffery P ^a   Pee, David ^b   McAdams, Mary ^b   Brody, Lawrence ^c   Tucker, Margaret ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INFORMATION MANAGEMENT SERVICES INC   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Biometry; Breast neoplasms; Colon neoplasms; Epidemiologic methods; Genetics; Jews; Ovarian neoplasms

Indexed keywords

ARTICLE; BINDING COMPETITION; BREAST CANCER; CANCER FAMILY; GENE FREQUENCY; GENETIC RISK; HETEROZYGOTE; HUMAN; INHERITANCE; JEW; PENETRANCE; PREVALENCE; RELATIVE;

EID: 0032191140     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/148.7.623     Document Type: Article

References (16)

1. Risch N. Segregation analysis incorporating linkage markers. 1. Single-locus markers with an application to type I diabetes. Am J Hum Genet 1984;36:363-86.
2. Easton DF, Ford D, Bishop DT, and the Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCAl-mutation carriers. Am J Hum Genet 1995;56:265-71.
3. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
4. Schatzkin A, Goldstein A, Freedman LS. What does it mean to be a cancer gene carrier? Problems in establishing causality from the molecular genetics of cancer. J Natl Cancer Inst 1995;87:1126-30.
5. Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11: 198-200.
6. Roa BB, Boyd AA, Volcik K, et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-7.
7. Oddoux C, Struewing JP, Clayton CM, et al. The carrier frequency of the BRCA 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996;14: 188-90.
8. Amos CL, Shaw GL, Tucker MA, et al. Age at onset for familial epithelial ovarian cancer. JAMA 1992;268:1896-9.
9. Khoury MJ, Flanders WD. Bias in using family history as a risk factor in case-control studies of disease. Epidemiology 1995;6:511-19.
10. Satten GA, Kupper LL. Inferences about exposure-disease associations using probability of exposure information. J Am Stat Assoc 1993;88:200-8.
11. Brinton LA, Daling JR, Liff JM, et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 1995;87:827-35.
12. Egan KM, Newcomb PA, Longnecker MP, et al. Jewish religion and risk of breast cancer. Lancet 1996;347:1645-6.
13. Kerber RA, Slattery ML. Comparison of self-reported and database-linked family history of cancer data in a case-control study. Am J Epidemiol 1997;146:244-8.
14. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results of three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;60:496-504.
15. Levy-Lahad E, Catane R, Eisenberg S, et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian families. Am J Hum Genet 1997;60:1059-67.
16. Easton D. Breast cancer genes - what are the real risks? Nat Genet 1997;16:210-11.